Video

Managing Symptoms For Patients With Myeloproliferative Neoplasms

Author(s):

Gabriela Hobbs, M.D.

Gabriela Hobbs, M.D., discusses how to manage symptoms associated with a myeloproliferative neoplasm diagnosis.

Gabriela Hobbs, M.D., of Massachusetts General Hospital in Boston, discusses how to manage symptoms associated with a myeloproliferative neoplasm (MPN) diagnosis.

These may include itching, fatigue, abdominal pain or discomfort, or early satiety — which may be treated by a variety of medications or changes in lifestyle.

Hobbs is currently working on a project to build a panel of patients to help focus on the unique symptoms of patients with MPNs.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
New Treatment Options Emerging for Across Lung Cancer Subtypes
Image of patient and doctor.
Understanding the Whole Person Behind their Cancer Diagnosis
Image of two doctors with text.
Delving Into Brain Cancer Treatment Takeaways Following ASCO 2025
image of gerds
Breaking Down the VERIFY Trial for Patients With Polycythemia Vera
Image of 2 doctors and text.
What Should Patients With Lung Cancer Know After ASCO 2025?
Image of two doctors and text.
Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025
Image of man.
A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment
Image of thumbnail.
What Patients With Genitourinary Cancers Should Know After ASCO 2025
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
How to Prepare for Self-Advocacy After a Cancer Diagnosis
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Enhertu Combo May Offer Longer Control for HER2+ Breast Cancer
Related Content
The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis: © stock.adobe.com.
June 16th 2025

FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis

Spencer Feldman
The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
From left: Katherine Mast Hagemann, B.S.N., RN, and Dr. Andrew Kuykendall
June 5th 2025

A Unicorn Among Us

Dr. Andrew Kuykendall
Katherine has an exquisite instinct for understanding that there is a context to each patient’s diagnosis that is just as important to understand.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Image of blood cells.
May 21st 2025

Evolving Myelofibrosis Treatments Aims to Fill Unmet Needs

Ryan Scott
JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.